From the impact of Obamacare to cutting-edge research, biotech buyouts to Big Pharma court battles, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry, and their implications for long-term investors. In this week's edition, the team talks about Novartis' patent dispute, stocks that have both popped and plummeted, and companies our analysts will be watching in the coming days.
In the following segment, health-care analyst Max Macaluso discusses President Obama's recent announcement of the $100 million "BRAIN Initiative" and how this project can help drugmakers, including Eli Lilly and Merck, that are developing new treatments for Alzheimer's disease.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.
The relevant video segment can be found between 4:02 and 5:27.
The article How the "BRAIN Initiative" Can Help Big Pharma originally appeared on Fool.com.
Brenton Flynn and Max Macaluso, Ph.D. have no position in any stocks mentioned. David Williamson owns shares of Pfizer. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.